CWON Press

South Korean biotech Lemonex is positioning its biodegradable porous-silica platform DegradaBALL as a non-LNP delivery option for mRNA, siRNA and other emerging medicines. Phase 1 human experience, a CEPI partnership and growing interest in alternative RNA carriers give the strategy scientific credibility — but the next test is proving that a modular delivery platform can translate across payloads, partners and commercial-scale manufacturing.

The global RNA therapeutics industry is entering a new phase. The success of messenger RNA vaccines demonstrated that nucleic acids can become medicines at unprecedented speed, but it also exposed a reality that is increasingly shaping biotechnology investment and pharmaceutical research: designing an RNA sequence is only part of the challenge. The therapeutic molecule must remain stable, reach the appropriate cells or tissues, enter those cells efficiently and produce its intended biological effect without creating unacceptable toxicity. That has made drug delivery one of the most strategically important technology layers in modern biopharma — and one South Korean biotechnology company, Lemonex Inc., is attempting to build its business around that bottleneck.

Founded in 2013 by Cheolhee Won and Seoul National University chemistry professor Dal-Hee Min, Lemonex has spent more than a decade developing DegradaBALL®, a biodegradable porous-silica nanoparticle drug-delivery system designed to carry pharmacologically active molecules within nanoscale pores and control their release after administration. The company has tested the platform with modalities ranging from siRNA and mRNA to proteins, cytokines and other biologics, while increasingly presenting DegradaBALL not as a single-product technology but as a modular delivery platform that could be licensed or supplied to multiple pharmaceutical partners.

That distinction is central to Lemonex’s strategy. Developing an individual drug requires a company to absorb the clinical, regulatory and commercial risk of that molecule. A successful delivery platform can theoretically participate in multiple drug programs simultaneously. In interviews with DealSite and The Bio, Lemonex has said it is pursuing collaborations ranging from applying DegradaBALL to partners’ existing candidates to supplying drug-delivery material, co-development and licensing arrangements. The long-term business thesis is therefore closer to an enabling-technology company than a conventional single-pipeline biotech.

Why Drug Delivery Has Become the Next RNA Battleground

Lipid nanoparticles, or LNPs, remain the most clinically validated non-viral systems for delivering nucleic acids and were crucial to the rapid deployment of COVID-19 mRNA vaccines. They should not be treated as obsolete technology: LNP-based formulations have been administered globally at enormous scale and continue to dominate much of RNA drug development. But their success has also accelerated research into alternative carriers that could offer different tissue distribution, storage characteristics, manufacturing strategies or tolerability profiles.

The question is increasingly not whether LNPs “work,” but whether one delivery architecture can optimally serve every RNA modality and therapeutic indication. Vaccines, personalized oncology, liver-directed therapies, local injections, self-amplifying RNA and extrahepatic gene modulation can place very different demands on a carrier. A 2026 review of silica-based nucleic-acid delivery systems described porous silica materials as an emerging alternative because their pore structure, composition and surfaces can be engineered while offering potential advantages in cargo protection and storage, although the field remains far less clinically mature than lipid delivery. The review specifically cited Lemonex’s DegradaBALL program as an example of biodegradable porous silica being developed for mRNA delivery.

This is the market opening Lemonex is targeting. Rather than arguing that every RNA therapy should abandon LNPs, the stronger commercial proposition is that pharmaceutical developers may increasingly need a portfolio of delivery technologies, selecting the system that best matches the biological target, administration route, desired release profile and manufacturing requirements of each program.

DegradaBALL Uses a Fundamentally Different Architecture

DegradaBALL is built from porous silica rather than lipids. The particles contain nanoscale pores capable of loading active pharmaceutical ingredients and are designed to biodegrade after administration. Lemonex says the platform can protect sensitive cargo, control release and reduce unnecessary systemic exposure by retaining more of the formulation around the intended site of delivery.

The architecture also creates an interesting manufacturing possibility. With conventional nucleic-acid nanoparticles, the active RNA and carrier often become deeply integrated during formulation. Lemonex has instead emphasized a modular approach in which DegradaBALL can be manufactured and stored separately before being combined with an active molecule. ClinicalTrials.gov describes LEM-mR203 as being prepared by mixing mRNA with DegradaBALL before administration, illustrating how the company has translated that concept into a human clinical formulation.

That separation could have practical implications if it remains robust at commercial scale. A standardized carrier could potentially be manufactured in advance, stored as inventory and later combined with different RNA constructs. For pandemic preparedness, where a pathogen sequence may change faster than manufacturing capacity can be built, pre-positioning part of the vaccine formulation could shorten one segment of the supply chain.

It is also important to be precise about stability claims. Lemonex has reported long-term temperature stability for DegradaBALL-based materials, and its website describes the platform as capable of storage at room temperature for more than two years. The company has separately said that CEPI-supported work confirmed up to 24 months of stability under multiple storage conditions. Those claims should not automatically be interpreted to mean that every final mRNA-DegradaBALL medicine containing a specific RNA payload has already been proven stable for two years at room temperature. Final-product stability remains formulation- and payload-dependent and must be established for each pharmaceutical product under relevant regulatory protocols. That distinction matters because it is precisely where platform promise must eventually meet pharmaceutical CMC reality.

The Most Important Evidence Is Already Human, Not Just Preclinical

Many novel delivery systems produce compelling animal data but never reach human testing. Lemonex has crossed that boundary. The most rigorous publicly available clinical evidence for DegradaBALL comes from LEM-S401, an siRNA candidate targeting connective tissue growth factor, or CTGF, for fibrotic skin conditions including hypertrophic scars and keloids. Results from its first-in-human Phase 1 study were published in Clinical and Translational Science in 2025.

The randomized, double-blind, placebo-controlled study enrolled 18 healthy volunteers and evaluated three subcutaneous dose levels containing 40, 100 or 200 micrograms of siRNA. Twelve participants received LEM-S401 and six received placebo. Drug-related adverse events were primarily mild injection-site pain and erythema that resolved without significant intervention. The published study reported no systemic adverse events and no significant cytokine differences between treatment and placebo groups.

Perhaps more relevant to the delivery thesis, the siRNA component LEM-17234 remained below the assay’s lower limit of quantification in plasma at measured time points. The investigators interpreted that result as indicating minimal systemic exposure after local administration. Silicon measurements, used to examine exposure related to the DegradaBALL carrier, also showed no clear dose-dependent systemic pattern.

These results do not prove clinical efficacy against scars, nor do they establish that every molecule delivered with DegradaBALL will behave similarly. The study involved only 18 healthy volunteers and one locally administered siRNA formulation. But from a platform-development perspective, the trial accomplished something important: it generated peer-reviewed first-in-human evidence that a porous-silica DegradaBALL formulation could be administered to people with a generally favorable early safety and tolerability profile. That is a considerably higher validation threshold than preclinical proof of concept alone.

A Second Phase 1 Program Extended the Platform Into mRNA

Lemonex subsequently brought DegradaBALL into a second modality through LEM-mR203, an mRNA COVID-19 booster vaccine studied at Seoul National University Hospital. ClinicalTrials.gov lists the Phase 1 study, NCT06032000, as completed. The randomized, placebo-controlled trial was designed to evaluate safety, reactogenicity and immune responses in healthy adults aged 19 to 55, with 20 participants enrolled. Unlike LEM-S401, the program used intramuscular administration and mRNA rather than subcutaneous siRNA, giving Lemonex a second human test of the carrier in a substantially different application.

Lemonex has publicly reported that no serious drug-related adverse reactions occurred during its interim safety analysis and that reported treatment-related reactions were predominantly mild local events. However, as of the latest accessible ClinicalTrials.gov record, detailed study results have not been posted to the registry. Those safety claims should therefore be distinguished from the peer-reviewed LEM-S401 data until the complete LEM-mR203 dataset is publicly available through a journal publication or registry results submission.

That distinction does not negate the significance of completing the study. Two separate human programs involving two different nucleic-acid payloads and different administration routes are unusual for an emerging non-LNP delivery technology. But publication of the full mRNA trial dataset — including immunogenicity, safety, pharmacodynamic and follow-up analyses — would materially strengthen external evaluation of the platform.

CEPI’s Investment Gave DegradaBALL an International Test

One of the most important external validations of Lemonex’s technology came from the Coalition for Epidemic Preparedness Innovations, or CEPI. In January 2024, CEPI announced that it would provide Lemonex with up to $4.6 million to evaluate the DegradaBALL mRNA vaccine platform in a Phase 1 clinical study and advance freeze-dried formulations aimed at reducing cold-chain requirements. The collaboration was positioned within CEPI’s broader strategy to identify next-generation RNA technologies that could improve stability, access, manufacturing and rapid outbreak response.

The project fits CEPI’s 100 Days Mission, an international effort to compress the time required to develop vaccines against a newly identified pandemic threat. CEPI’s vision includes maintaining reusable platform technologies and vaccine-development resources that can be rapidly adapted when a new pathogen emerges. Under that logic, delivery technologies are not peripheral components. They determine how quickly a newly designed RNA vaccine can become a stable, manufacturable and distributable pharmaceutical product. CEPI’s subsequent mid-term review identified Lemonex among the platform-development efforts that had advanced into human testing, providing further evidence that DegradaBALL was being evaluated not simply as a domestic Korean R&D project but within a broader global pandemic-preparedness framework.

South Korea Is Also Treating RNA Delivery as Strategic Infrastructure

Lemonex’s development has also become part of South Korea’s national push to secure domestic mRNA capabilities. In 2025, the Korea Disease Control and Prevention Agency selected Lemonex, GC Biopharma, EuBiologics and Korea BMI as lead organizations in the nonclinical stage of its Pandemic Preparedness mRNA Vaccine Development Support Program. The broader program is designed to invest KRW 505.2 billion through 2028 across nonclinical and clinical stages with the objective of building domestically controlled mRNA vaccine capabilities.

Public R&D records show a Lemonex-led project involving a DegradaBALL-based COVID-19 mRNA candidate with total research funding of approximately KRW 6 billion over an 11-month period from April 2025 through February 2026. The strategic context is larger than COVID-19. The pandemic exposed how countries without independent access to core vaccine technologies could become dependent on overseas manufacturing, intellectual property and supply chains during periods of extraordinary global demand. Developing domestic RNA synthesis without domestic delivery technology only partially solves that dependency. That is one reason delivery systems have become a form of biotechnology infrastructure.

The Next Frontier Is Longer and More Complex RNA

Lemonex is now discussing applications beyond conventional mRNA and siRNA. In its recent interview with The Bio, the company said it is researching delivery of self-amplifying RNA, or saRNA, including molecules around 10 kilobases in length. That is scientifically significant because longer RNA molecules can impose more demanding formulation requirements. saRNA is designed to replicate intracellularly, potentially producing substantial antigen or therapeutic protein expression from a lower initial RNA dose. But increased molecular length also makes the RNA more fragile and can complicate encapsulation, delivery and manufacturing.

A platform capable of handling both short siRNA and substantially longer RNA constructs would therefore have broader commercial utility. But this is also an area where proof will matter more than platform claims. Demonstrating loading capacity is not enough; developers must show preservation of RNA integrity, reproducible intracellular delivery, functional protein expression, appropriate biodistribution and an acceptable safety profile. The next generation of RNA delivery will increasingly be judged by exactly those parameters.

Beyond RNA: Lemonex Wants DegradaBALL to Become a Broader DDS Platform

Lemonex’s ambitions extend beyond nucleic acids. The company lists programs involving cytokines and immuno-oncology candidates, including BALLkine-2, which applies DegradaBALL to interleukin-2. The underlying idea is to alter the release and distribution of a potent therapeutic protein whose systemic exposure can cause substantial toxicity. Lemonex reports preclinical data showing reduced systemic exposure and increased local tumor exposure in animal studies.

The company has also discussed applications involving proteins, antibodies, growth factors, peptides and other active ingredients. This breadth is strategically attractive but scientifically demanding. Every additional modality expands the addressable market, yet each also introduces different loading chemistry, release kinetics, biological activity and regulatory questions. A carrier optimized for siRNA does not automatically become optimal for an antibody, cytokine or long RNA molecule. The ultimate value of a modular DDS platform will therefore depend not on how many modalities it can theoretically carry, but on how many can generate reproducible, differentiated development programs.

Why the Business Model May Matter as Much as the Science

Lemonex’s commercial strategy is designed around that modularity. DealSite reported in March that the company was pursuing multiple technology-transfer partnerships and considering eventual expansion into DDS-focused contract development and manufacturing. The company has said that a platform model could allow it to form multiple non-exclusive collaborations rather than depending on the success of a single therapeutic asset.

The Bio’s August interview shows that the strategy has evolved toward a broader concept of Lemonex as a “global technology partner” — working with drug developers from formulation and preclinical testing through material supply, CMC, co-development and licensing. That model resembles the way several successful life-science platform companies have created value: own a difficult enabling technology, validate it across multiple programs and allow partners to bring their own therapeutic assets into the system. For Lemonex, the potential advantage is risk diversification. A conventional biotech can lose much of its value when a single lead drug fails. A delivery company with multiple external programs could theoretically spread biological risk across payloads and partners.

But platform economics have their own challenges. Pharmaceutical companies will require strong intellectual-property protection, reproducible manufacturing, rapid technology transfer, regulatory documentation and enough capacity to support several programs without compromising quality. Once partners move into late-stage trials, material consistency can become as important as scientific novelty. In other words, a delivery platform eventually becomes a manufacturing and CMC business as much as a nanotechnology business.

CDMO Could Be the Logical End Point — but It Raises the Bar

Lemonex has publicly discussed the possibility of expanding into a DegradaBALL-based CDMO business after securing additional capital. The company says it already operates infrastructure capable of manufacturing clinical-trial material and has accumulated production and process data for the platform. The logic is clear. If a pharmaceutical company licenses a proprietary delivery platform, it will eventually need a reliable source of GMP-grade carrier material, validated analytical methods, release specifications and potentially integrated formulation support. Supplying those services internally could allow Lemonex to capture more value than licensing intellectual property alone. It could also create a recurring revenue layer.

But CDMO expansion requires substantial capital and operational discipline. Commercial-scale biopharmaceutical manufacturing is judged on batch reproducibility, deviation control, quality systems, analytical validation, supply-chain resilience and regulatory inspection readiness. The business is less forgiving than early-stage research. A successful transition would therefore require Lemonex to prove that DegradaBALL is not only scientifically differentiated but industrially reproducible.

LNP Is the Benchmark, Not the Enemy

One of the most important questions surrounding any non-LNP company is whether it is truly necessary to “replace” lipid nanoparticles. That may be the wrong question. LNPs have an enormous clinical and manufacturing head start. They have validated nucleic-acid delivery at global scale, and pharmaceutical companies continue to invest heavily in improving their chemistry, tissue targeting and tolerability. A new platform does not have to make LNP obsolete to become valuable. It needs to be better somewhere that matters.

That could mean a particular administration route, reduced systemic exposure, improved storage, easier point-of-use formulation, a payload that is difficult to encapsulate in conventional systems or delivery to a biological compartment that current LNPs do not reach efficiently. The Bio interview reflects a similar positioning from Lemonex: the company’s stated goal is not simply to win a universal performance competition against LNPs, but to provide drug developers with another delivery option when conventional systems do not optimally fit a candidate. That is a more realistic — and potentially more valuable — strategy.

From Korean Nanotechnology to a Global Platform Business

What makes Lemonex worth watching is the combination of several forms of validation that rarely occur simultaneously in an early delivery company. The technology originated from academic nanomaterials research. It has moved into two human clinical programs involving different nucleic-acid modalities. One Phase 1 study has already produced peer-reviewed clinical data. CEPI selected the mRNA platform for funding within its pandemic-preparedness strategy. South Korea’s public health system selected Lemonex for a national mRNA vaccine-development program. And the company is now attempting to convert that technical foundation into multiple pharmaceutical partnerships rather than relying exclusively on internally developed drugs.

None of those achievements guarantees commercial success. But together they move DegradaBALL into a different category from a delivery technology supported only by promising cell and animal experiments. For Lemonex, the next phase will be less about proving that porous silica can carry a drug and more about proving that DegradaBALL can become a repeatable pharmaceutical development system: one that works with different payloads, can be transferred to partners, is manufacturable under GMP, survives regulatory scrutiny and ultimately produces meaningful benefits for patients.

The Bigger Question Is Whether RNA Delivery Becomes a Multi-Platform Market

The broader industry may be moving in Lemonex’s favor. RNA medicines are expanding beyond first-generation infectious-disease vaccines toward personalized cancer vaccines, gene regulation, protein replacement, self-amplifying RNA and other therapeutics. As the applications diversify, the assumption that one delivery technology will serve every modality becomes harder to sustain.

That could create a market resembling other mature pharmaceutical technology sectors, where developers choose among multiple formulation and delivery approaches depending on the product. If that happens, the commercial winner may not necessarily be the company that invents a universal replacement for LNP. It may be the companies that build well-characterized, clinically validated delivery platforms for the situations in which LNP is not the optimal solution.

Lemonex is betting that DegradaBALL can become one of those platforms. The company’s human data, CEPI relationship and developing manufacturing strategy give that ambition more substance than it had several years ago. But the decisive evidence will come from the next generation of programs — particularly partner-owned payloads, larger clinical studies and pharmaceutical-scale manufacturing. The RNA revolution proved that genetic information itself can become medicine. The next competitive race is over who can deliver it. And that is precisely where Lemonex has chosen to compete.